What is a clinical hold? It's an order from FDA, the U.S. drug regulator, delaying or stopping specified research in people. Lifting a hold lets that research proceed; it doesn't give permission to market the drug.
What is a clinical hold under FDA rules?
Under the FDA's clinical-hold explanation, the order goes to the sponsor, the person or organization responsible for the research.
It concerns research under an IND, short for Investigational New Drug application. The FDA's IND overview describes the filing that supports testing a drug in people.
21 CFR 312.42 sets the hold rules.
Full versus partial clinical holds
A full hold delays or suspends all studies under the affected IND. A partial hold stops only specified work. Other studies, or permitted parts of a study, may continue. Partial describes the scope of the restriction, not how serious the concern is.
Why FDA can stop a study
The purpose is to protect participants before more people are exposed to an unresolved problem. Grounds include unreasonable and significant risk, missing safety information, unqualified investigators or misleading information supplied to researchers. Later-stage studies can also be held for a seriously flawed study plan.
A hold doesn't always follow an injury. Lapteva and Pariser's study in the Journal of Investigative Medicine, 2016 examined initial applications. Product chemistry and manufacturing issues were the most commonly cited reasons for holds.
A hypothetical peptide headline: what document matters?
Hypothetical reading exercise: imagine a future MOTS-c study with a headline saying its trial has paused. MOTS-c is a peptide, a short chain of amino acids, the building blocks of proteins.
An FDA hold would be documented by an agency order naming the affected investigation and the reason. FDA can give rapid notice first; a written explanation follows within 30 days.
A company announcement saying only “paused” doesn't establish that FDA acted. The molecule's name alone doesn't identify the sponsor, study or restriction.
What does “clinical hold lifted” mean?
It means FDA has notified the sponsor that the affected investigation may proceed. The sponsor has addressed the cited problems or otherwise satisfied FDA that the research can continue.
FDA's complete-response guidance, issued October 2000, explains the review process. A complete response addresses all the hold issues. Under the regulation, FDA must respond in writing within 30 calendar days after receiving that response and a written request to remove the hold. Its decision can maintain the hold. The deadline doesn't authorize an automatic restart.
Holds can last months. Wills and colleagues, Molecular Therapy Methods & Clinical Development, 2023 analyzed 33 publicly announced holds involving cell and gene therapies, treatments using cells or changes to genetic material. Roughly 4 in 5 had been lifted by the study's close; the reported average duration was 6.2 months.
That selected group cannot predict a future peptide study's timeline. In the hypothetical MOTS-c example, a lifted hold would answer whether the specified research could resume. It would not establish treatment benefit or settle the evidence for a pharmacy preparation.
Clinical hold vs trial suspension: who pressed pause?
An FDA hold is a regulatory order. A sponsor pause is a decision by the organization running the research. A sponsor may stop dosing to investigate a safety concern before FDA acts. FDA's staff procedure explicitly allows a later agency hold after such a safety stop.
“Suspended” by itself doesn't name the decision-maker. The useful details are who acted, which study activities stopped and what must happen before they restart. A safety pause deserves attention even when it isn't an FDA order.
Two other common mistakes are reading “partial” as “minor” and reading “lifted” as proof the drug works. Neither conclusion follows from those words.
For affected ongoing research, new participants cannot be recruited and given the study drug. People already receiving it should be taken off that treatment unless FDA specifically permits continuation for patient safety. The study team handles those instructions.
FDA procedure updates in 2026
As of November 12, 2026, the day this article was written, FDA's updated clinical-hold staff procedure carries “Effective Date: January 14, 2026.” These instructions cover its center overseeing medicines made from living sources. The changes include how to communicate a hold when a sponsor cannot be reached.
Separately, FDA's September 15, 2026, pilot announcement aims to identify problems earlier by reviewing application parts as they become ready. FDA keeps authority to impose holds.
What this means for a peptide prescription
Study access and an individual prescribing decision answer different questions. A routine prescription doesn't enroll someone in a clinical trial or supply the paperwork needed to restart held research.
MOTS-c prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, prepared for an individual prescription. It is different from an FDA-approved product: the formulation offered here is not FDA-approved. FDA explains that it does not review compounded drugs for safety, effectiveness or quality before marketing.
A licensed provider may still prescribe — that decision is between you and your doctor.
At Promise, a licensed provider reviews every request, and not everyone qualifies.
Related terms that help the headline make sense
An IND application explains the filing behind the investigation. The phases of clinical trials explain what stage of testing a study has reached. Neither term replaces the actual hold decision.
For someone comparing a trial headline with a prescription option, the useful questions stay concrete: which product was studied, which participants were involved, and what did FDA actually permit? A research restart answers only the question in the agency's notice.





